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Background/Aims: A two-year, prospective, nationwide 
multicenter study was undertaken to evaluate the effect of 
Helicobacter pylori eradication on the development of reﬂ  ux 
esophagitis (RE) and gastroesophageal reﬂ  ux disease (GERD) 
symptoms in the Korean population. Methods: In total, 
1,489 subjects without RE were enrolled at the outpatient 
clinics of 12 tertiary hospitals nationwide, and 452 subjects 
underwent follow-up (F/U) for 2 years to evaluate the devel-
opment of RE and GERD symptoms. Results: RE was found 
in 33 subjects (7.3% of 452 subjects) and 14 subjects (7.3% 
of 192 subjects) during the first and second year of F/U, 
respectively. H. pylori status was not associated with the de-
velopment of RE. RE was found in six (9.0%) of 67 H. pylori-
negative patients, in 26 (11.2%) of 233 eradicated subjects 
and in eight (7.0%) of 114 noneradicated subjects (p=0.532). 
Multivariate analysis showed that age ≥60 years (odds ratio 
[OR], 7.11; 95% conﬁ  dence interval [CI], 1.92 to 26.41), al-
cohol consumption (OR, 4.43; 95% CI, 1.03 to 19.19) and F/
U cholesterol levels ≥200 mg/dL (OR, 5.03; 95% CI, 1.32 to 
19.17) were significant risk factors for the development of 
RE. There was no signiﬁ  cant difference in the development 
of GERD symptoms or weight according to H. pylori status 
during the 2-year F/U. Conclusions: Eradication of H. pylori 
did not affect the development of reﬂ  ux esophagitis or GERD 
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symptoms among patients in outpatient gastroenterology 
clinics in South Korea. (Gut Liver 2011;5:437-446)
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INTRODUCTION
Helicobacter pylori (H. pylori) infection plays a major role in 
the pathogenesis of peptic ulcer disease, chronic gastritis, gastric 
mucosa-associated lymphoid tissue lymphoma (MALToma), and 
the development of gastric cancer. However, its role in reflux 
esophagitis (RE) or gastroesophageal reflux disease (GERD) is 
not fully understood. In addition, the effect of H. pylori eradica-
tion on RE or GERD is unclear. Several reports have shown an 
association of H. pylori eradication with the development of 
RE
1-5 or GERD symptoms.
6,7 However, contradictory results have 
been reported
8-11 and sometimes a beneficial effect of H. pylori 
eradication on GERD has been observed.
12-16 This issue regard-
ing the effect of H. pylori eradication on the development of RE 
is important because RE often requires chronic treatment with 
a proton pump inhibitor (PPI) due to frequent relapse of symp-
toms.
17 The Maastricht III Consensus Report already extended 
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dyspepsia, along with those who chronically use PPI or non-
steroid anti-inflammatory drugs (NSAID).
18 In South Korea, the 
eradication of H. pylori has been rapidly increasing
19,20 as well 
as the prevalence of RE
21 or Barrett’s esophagus.
22 Therefore, if 
RE development increases after eradication of H. pylori, then the 
eradication of H. pylori should proceed with greater caution in 
South Korea.
Based on this background, a nationwide multicenter prospec-
tive study was undertaken to evaluate the effect of H. pylori 
eradication on the development of RE and GERD symptoms in 
South Koreans. In addition, factors affecting RE development 
were evaluated. 
MATERIALS AND METHODS
1. Subjects 
This study was designed by the Scientific Committee of the 
Korean College of Helicobacter and Upper Gastrointestinal Re-
search. A workshop was held on June 25, 2005 to approve the 
study design and to standardize the description of RE and gas-
troesophageal reflux symptoms in the questionnaire. Feedback 
from experts in this field and practical field tests were conducted 
to validate the reflux symptom questionnaire over 3 months.
23 
Patients with gastritis, duodenal ulcers (DU) in the active or 
healing stages, and benign gastric ulcer (BGU) were enrolled in 
July 2006 for 1 year at the Gastroenterology Department of 12 
tertiary hospitals nationwide. Most of the participants had gas-
troduodenal discomfort and underwent endoscopy to evaluate 
whether the symptoms were related to specific diseases such as 
gastric cancer, DU, BGU, or RE. Subjects with a previous history 
of gastric surgery, H. pylori eradication treatment, or systemic 
diseases requiring chronic medication were excluded. In ad-
dition, subjects current taking or with a history of taking H2 
blocker or PPI within at least 1 month were excluded from this 
study. Subjects with upper gastrointestinal endoscopy results 
showing evidence of RE, gastric cancer, dysplasia, MALToma, 
or esophageal cancer were excluded from this study. Addition-
ally subjects with endoscopic findings of BGU scars or DU scars 
were also excluded from enrollment to avoid confusion in the 
analysis. The Institutional Review Board of the 12 participating 
hospitals approved this study, and written informed consent 
was obtained from all participants.
2. Upper gastrointestinal endoscopic examinations 
All study subjects underwent upper gastrointestinal endo-
scopic examinations. The endoscopic findings of RE in the lower 
esophagus were classified according to the Los Angeles (LA) 
classification based on the longest length of the mucosal break, 
and confluence of erosions. A hiatal hernia was endoscopically 
defined as a distance from the esophagogastric junction to the 
diaphragmatic impingement of more than 1 cm. The esopha-
gogastric junction was defined as the proximal margin of the 
gastric mucosal fold.
24
3. Questionnaire
Patients who agreed to participate in the study were inter-
viewed in person by an assistant using the gastroesophageal 
reflux questionnaire, before the endoscopy. The questionnaire 
included questions about seven reflux symptoms including 
heartburn, acid regurgitation, chest pain, hoarseness, globus 
sensation, cough, and epigastric soreness. The questions were as 
follows: 1) Have you experienced heartburn? 2) Have you expe-
rienced acid regurgitation? 3) Have you experienced chest pain? 
4) Have you experienced hoarseness? 5) Have you experienced 
a globus sensation in the throat? 6) Have you experienced a 
frequent cough? 7) Have you experienced epigastric soreness? 
If the patients replied yes to at least one of the seven questions 
about reflux symptoms, then they were further questions about 
the reflux symptom periods. Body mass index (BMI) and the 
results of biochemical testing including glucose, cholesterol, tri-
glyceride, and H. pylori tests were recorded by assistants. 
4. H. pylori tests
Two biopsy specimens from the antrum and two from the 
body were fixed in formalin, and examed for the presence of 
H. pylori by modified Giemsa staining. One specimen from the 
lesser curvature of the antrum and one from the corpus were 
subjected to rapid urease testing (Campylobacter-like organism 
(CLO) test; Delta West, Bentley, Australia). H. pylori infection 
was diagnosed when at least one of these tests gave positive re-
sults.
5. Serum pepsinogen levels
Fasting serum was collected from all subjects at the beginning 
of the study. The samples were centrifuged immediately and 
stored at -70
oC until used. Serum concentrations of pepsinogen 
(PG) I and II were measured using a latex-enhanced turbidimetic 
immunoassay (L-TIA) (HBi Co., Seoul, Korea, imported from 
Shima Laboratories, Tokyo, Japan), and PG I to PG II ratios (PG 
I/II) were calculated.
25,26
6. Eradication treatments and follow-up study
When a subject with duodenal or gastric ulcers was found to 
be H. pylori-positive, the standard 7-day triple therapy (PPI b.i.d., 
500 mg b.i.d. clarithromycin, and 1 g b.i.d. amoxicillin) was 
started for H. pylori eradication. Subjects with simple gastritis 
also received H. pylori eradication therapy when requested by 
the patient. To determine whether H. pylori had been eliminat-
ed, 
13C-urea breath testing was performed at least 4 weeks after 
completing the triple therapy. If H. pylori infection was found 
to present persistent after the first-line PPI-based triple therapy 
a 1- or 2-week course of bismuth-based quadruple therapy was 
started: 20 mg b.i.d. esomeprazole, and 300 mg q.i.d. tripotas-
sium dicitrate bismuthate (DENOL®; Greencross, Seoul, Korea, Kim N, et al: Eradication of H. pylori and Reflux Esophagitis  439
three tabs taken 30 minutes before meals and one tab taken 2 
hours after dinner), 500 mg t.i.d. metronidazole, and 500 mg 
q.i.d. tetracycline.
Initially enrolled subjects underwent endoscopy and filled out 
a questionnaire every year for 2 years. The endoscopists were 
unaware of the questionnaire results. Patients with recurrence 
or occurrence of BGU were excluded from this study. Every 
participant was asked whether new GERD symptoms (heartburn, 
acid regurgitation, chest pain, hoarseness, globus sensation, 
cough, and epigastric soreness) had developed during follow-up 
period. In addition, patients answered questions about duration 
and frequency of their symptom (a. 1-2 times per year, b. 1-2 
times per month, c. 1-2 times per week, d. 3-4 times per week, e. 
daily). In addition, they were asked whether they took PPI or H2 
blocker to relieve these GERD symptoms, and were also asked 
about the duration of PPI or H2 blocker treatment. If the partici-
pants refused the follow-up endoscopy at the second year in af-
ter numerous requests, an interview was conducted to evaluate 
changes in weight, smoking habits, and alcohol consumption. 
In addition, the questionnaire regarding gastroesophageal reflux 
symptoms was re-administered. The main reason for refusal of 
endoscopy at the second year was that the patient disliked un-
dergoing the procedure. 
7. Statistical analysis
The patients were categorized according to age in 10-year 
intervals. New development of reflux esophagitis and GERD 
symptoms (heartburn, acid regurgitation, chest pain, hoarseness, 
globus sensation, cough, and epigastric soreness) follow-up pe-
riod was analyzed according to H. pylori eradication. Chi-square 
tests were performed to assess the association between each 
covariate and development of RE. Covariates that showed sig-
nificant association by the chi-square tests were considered for 
the multiple logistic regression analyses. Model fit was assessed 
by the Hosmer-Lemeshow goodness-of-fit test. The variables 
that were significant in the model or improved model fit were 
included in the final model. The final models showed an ap-
propriate goodness of fit (p>0.10). All analyses were performed 
using SAS statistical software (SAS Institute, Cary, NC, USA). A 
p-value of less than 0.05 was considered statistically significant. 
RESULTS
1. Characteristics of participants 
In total 1,489 subjects (855 males, 57.4%; 634 females, 
42.6%) were included in the study. The mean age was 51.3 
years and all participants were ethnically Korean. Follow-up en-
doscopy with the questionnaire was performed 1 year later and 
452 subjects received an endoscopy 1 year after enrollment. The 
characteristics of 452 subjects are described in Table 1 including 
gender, age, BMI, endoscopic diagnosis, smoking habit, alcohol 
consumption, hiatal hernia, glucose, cholesterol, triglyceride, H. 
pylori infection, and pepsinogen levels. There were no statisti-
cal differences in these variables between the 1,489 initially 
enrolled and 452 follow-up subjects. Four hundred fifty-two 
subjects had DU in the active or healing stage (68, 15.1%), BGU 
in the active or healing stage (115, 25.4%), or gastritis (269, 
59.5%). There were 385 individuals (85.2%) with H. pylori infec-
tions and the remaining 67 subjects (14.8%) were not infected. 
When reflux symptoms of 452 subjects were analyzed at en-
rollment, epigastric soreness was the most frequent symptom, 
reported by 127 subjects (28.1%), followed by heartburn (27 
subjects, 6.0%), chest pain (25 subjects, 5.5%), acid regurgita-
tion and globus sensation (21 subjects, 4.6%), cough (7 subjects, 
1.5%), and hoarseness (2 subjects, 0.4%). 
Table 1. Baseline Characteristics of the Initially Enrolled Subjects and 
Patients Undergoing Follow-Up for 2 Years
Variable category
Initially enrolled
 subjects (n=1,489)
Followed-up
  subjects (n=452) 
Gender 
   Male 855 (57.4) 271 (60.0)
   Female 634 (42.6) 181 (40.0)
Age, yr 51.3±12.4 53.8±11.1
   16-29 60 (4.0)     5 (1.1)
   30-39 206 (13.9)   46 (10.2)
   40-49 402 (27.0) 106 (23.4)
   50-59 420 (28.2) 142 (31.4)
   60-69 301 (20.2) 121 (26.8)
   ≥70 100 (6.7) 32 (7.1)
Body mass index 23.8±3.2 23.9±3.1
Endoscopic diagnosis 
   Duodenal ulcer 
     (active or healing stage)
336 (22.6)   68 (15.1)
   Benign gastric ulcer 
     (active or healing stage)
333 (22.3) 115 (25.4)
   Gastritis 820 (55.1) 269 (59.5)
Smoking (current:past)   387 (26.0):115 (7.7)  108 (23.9):51 (11.3)
Alcohol consumption 
  (current:past)
624 (41.9):52 (3.5) 203 (44.9):21 (4.6)
Hiatal hernia 60 (4.0) 16 (3.5)
Glucose, mg/dL 103.1±30.2  102.5±31.4
Cholesterol, mg/dL 188.6±39.4 187.7±38.8
Triglyceride, mg/dL 136.6±50.5 139.1±48.9
H. pylori infection 1189 (79.9) 385 (85.2)
Pepsinogen level 
   Pepsinogen I, ng/mL 65.5±23.1 69.0±22.1
   Pepsinogen II, ng/mL 18.6±11.3 18.4±11.2
   Pepsinogen I/II ratio  3.95±1.55 3.75±1.64
Data are presented as mean±SD or number (%).440  Gut and Liver, Vol. 5, No. 4, December 2011
2. H. pylori treatment results and weight change during the 
2-year follow-up
Among the 452 subjects who had received an endoscopy 
1 year after enrollment, 192 (42.5%) another endoscopy in 
the second year of follow-up, and the remaining 260 subjects 
(57.5%) responded to a telephone interview. Initially, 67 sub-
jects (14.8%) were diagnosed as H. pylori-negative. Among 385 
H. pylori-positive cases, 233 cases (51.6%) were found to be 
eradicated, 114 subjects (25.2%) were not treated or the infec-
tion was not eradicated, and 38 (8.4%) did not receive follow-
up H. pylori tests (Table 2). Participants were weighted prior to 
enrollment and 1 and 2 years after enrollment, there was no 
significant difference in weight based on the H. pylori status 
during follow-up.  
3. Development of reflux symptoms during the 2-year fol-
low-up depending on H. pylori eradication 
Analysis based on development of reflux-related symptoms 
during the 2-year follow-up was performed according to H. py-
Table 2. Weight Changes Based on H. pylori Eradication in the 452 Follow-Up Subjects
Variable No. (%) Initial, kg 1 yr later, kg 2 yr later, kg
H. pylori-negative   67 (14.8)  63.0±12.1* 64.7±12.7 63.9±11.7
H. pylori-positive 385 (85.2)   
   Eradicated after treatment 233 (51.6) 63.7±11.0 63.9±11.2 63.4±9.8
   Untreated or persistent infection 114 (25.2) 63.1±11.1 64.8±11.0 64.8±11.3 
   No test after eradication 38 (8.4) 64.9±11.5 65.1±11.8 64.9±11.6
*Mean±SD.
Table 3. The Development of Reflux Symptoms During the 2-Year Follow-Up Based on H. pylori Eradication 
Symptom*
H. pylori-negative 
(n=67) 
H. pylori-eradicated 
(n=233) 
Persistent H. pylori infection
(n=114) 
p-value
Heartburn  2 (3.0)  8 (3.5) 6 (5.3)    0.537
Acid regurgitation  4 (6.0) 17 (7.4) 7 (6.2)    0.736
Chest pain  2 (3.0)  6 (2.7) 6 (5.7)    0.591
Hoarseness  0 (0)  1 (0.4) 0 (0)    0.195 
Globus sensation  2 (3.0)  8 (3.5) 1 (0.9)    0.185
Cough  4 (6.0) 3 (1.3) 1 (0.9)    0.514
Epigastric soreness  7 (10.5) 3 (1.3) 1 (0.9)    0.901
Data are presented as number (%).
*The occurrence of each symptom was counted individually.
Fig. 1. Development of reflux 
esophagitis, as determined by the 
Los Angeles (LA) grades at follow-up 
(F/U) endoscopic examinations after 
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Table 4. Univariate Analysis of Reflux Esophagitis Development during the 2-Year Follow-Up 
Variable 
Non-reflux esophagitis 
(n=409) 
Reflux esophagitis
(n=43) 
Total 
(n=452) 
p-value
Gender  0.088
   Male 240 (58.7) 31 (72.1) 271 (60.0)
   Female 169 (41.3) 12 (27.9) 181 (40.0)
Age, yr  0.032
   16-39   46 (11.3)   5 (11.6)   51 (11.3)
   40-59 232 (56.7) 16 (37.2) 248 (54.9)
   ≥60 131 (32.0) 22 (51.2) 153 (33.8)  
H. pylori eradication state  (n=374) (n=40) (n=414) 0.532
   H. pylori-negative 61 (16.3)   6 (15.0)   67 (16.2)
   Eradicated 207 (55.4) 26 (65.0) 233 (56.3)
   Noneradicated 106 (28.3)   8 (20.0) 114 (27.5)
Smoking habit  (n=341)  (n=31) (n=372) 0.054
   Nonsmoking-nonsmoking 260 (76.2) 20 (64.5) 280 (75.3)
   Nonsmoking-smoking 21 (6.2) 2 (6.5) 23 (6.2)
   Smoking-nonsmoking   3 (0.9) 2 (6.5)   5 (1.3)
   Smoking-smoking   57 (16.7)   7 (22.6)   64 (17.2)
Alcohol consumption  (n=340) (n=30) (n=370)
   Nonalcohol-nonalcohol 199 (58.5)   9 (30.0) 208 (56.2) 0.006
   Nonalcohol-alcohol   37 (10.9)   3 (10.0)   40 (10.8)
   Alcohol-nonalcohol   4 (1.2) 0 (0)   4 (1.1)
   Alcohol-alcohol 100 (29.4)  18 (60.0) 118 (31.9)
Initial finding of hiatal hernia 0.160
   Yes  12 (3.5) 3 (7.0) 15 (3.3)
   No 397 (96.5) 40 (93.0) 437 (96.7)
Disease  0.012
   Duodenal ulcer   60 (14.7)   8 (18.6)   68 (15.0)
   Benign gastric ulcer   96 (23.5) 19 (44.2) 115 (25.5)
   Gastritis 253 (61.8) 16 (37.2) 269 (59.5)
Pepsinogen 
   Pepsinogen I, ng/mL 60.6±12.1 75.9±17.9 65.5±23.1 0.035
   Pepsinogen II, ng/mL 18.5±11.7 18.2±12.0 18.6±11.3 0.893
   Pepsinogen I/II ratio 3.68±1.11 4.41±1.28 3.95±1.55 0.043
Weight  
   Initial weight, kg 62.9±0.54 67.1±1.98 64.2±1.11 0.094
   Follow-up weight, kg 63.9±0.61 69.4±2.17 64.3±1.13 0.018
Cholesterol 
   Initial, mg/dL 187.7±12.1 187.5±7.8 187.7±10.8 0.981
   Follow-up, mg/dL 188.7±8.1 211.5±10.0 190.9±9.2 0.047
Triglyceride 
   Initial, mg/dL 139.6±6.1 131.9±18.2 139.0±9.8 0.730
   Follow-up, mg/dL 144.2±9.6 141.1±25.8  144.0±110 0.861
Data are presented as mean±SD or number (%).442  Gut and Liver, Vol. 5, No. 4, December 2011
lori infection (Table 3). New development of epigastric soreness 
was the most common symptom, especially in the H. pylori-
negative group (10.5%) but there was no statistical significance 
associated with H. pylori infection. The percentage of partici-
pants with new development of other reflux symptoms such 
as heartburn, acid regurgitation, chest pain, hoarseness, globus 
sensation and cough were found to be 0% to 6.0%, there was 
no significant difference associated with H. pylori eradication 
(Table 3).  
4. Development of RE during the 2-year follow-up 
RE was found in 33 subjects (7.3% of 452 subjects) and 14 
subjects (7.3% of 192 subjects) at the first and second year of 
follow-up, respectively. Among the 33 patients who developed 
RE at the 1st follow-up 30 (90.9%) showed LA-A and 3 (9.1%) 
showed LA-B (Fig. 1). Among the 30 subjects with LA-A at the 
first follow-up, 27 did not have RE at the second year and three 
subjects were found to have persistent LA-A (Fig. 1). Among 
the three subjects with LA-B, only one had persistent LA-B at 
the second year follow-up. Ten subjects who did not have RE at 
the first year follow-up turned out to have LA-A (nine subjects) 
or LA-B (one subject) at the second year follow-up. Finally, RE 
was found in 14 subjects at the second year follow-up (Fig. 1). 
In summary, there were 33 RE patients at the first year follow-
up, and cases of RE were found in 14 patients RE patients at the 
second year follow-up. Three patients continuously had LA-A 
and one patient persistently showed LA-B at the first and sec-
ond year follow-up, respectively. In total, RE developed in 43 
patients during the 2-year follow-up period.
5. Analysis of risk factors for RE development 
To evaluate the risk factors for RE during the 2-year follow-
up period, univariate analysis was performed to examine gen-
der, age, H. pylori eradication, smoking habit, alcohol consump-
tion, initial finding of hiatal hernia, underlying disease, serum 
pepsinogen, weight changes, and cholesterol and triglyceride 
levels (Table 4). Gender showed no correlation with RE develop-
ment but there was an increase of RE incidence with age (14.4% 
≥60 years vs 6.4% 40 to 59 years). H. pylori eradication was not 
associated with RE development of RE. That is, among 67 H. 
pylori-negative patients, RE development was found in 6 (9.0%), 
RE development was found in 26 (11.2%) out of 233 subjects 
in which H. pylori had been eradicated, and RE developed in 8 
(7.0%) out of 133 patients with persistent H. pylori infections 
(p=0.532). Smoking showed a marginal difference in RE devel-
opment, but alcohol consumption had a statistically difference 
impact (Table 5). That is, the nonalcohol-nonalcohol group had 
4.3% RE, the alcohol-nonalcohol group 0%, which was lower 
than the nonalcohol-alcohol group 7.5%, and the alcohol-
alcohol group showed 15.2% (p=0.006). The presence of an un-
derlying disease was found to influence the development of RE. 
RE development was frequent observed in patients with BGU 
(16.5%), this was more common than in patients with DU (11.8%) 
or gastritis (5.9%) (p=0.012). Serum pepsinogen level was also 
associated with development of RE. PG I levels were higher in 
the group that developed RE (75.9±17.9 ng/mL) than in the 
group that did not develop RE (60.6±12.1 ng/mL) (p=0.035); 
however, there was no significant difference in the PG II levels 
between these 2 groups. Finally, the PG I/II ratio was higher 
in the RE group (4.41±1.28) than in the group without RE 
(3.68±1.11) (p=0.043). Initial body weight was not significantly 
associated with the development of RE. However, body weight 
was increased in the RE group at follow-up, and this was sig-
nificantly associated with RE development (p=0.028). Similar 
to body weight, cholesterol levels also showed a significant as-
sociation with the development of RE in the univariate analysis. 
Initial cholesterol levels were similar between the groups with 
and without RE. However, the follow-up cholesterol levels were 
higher in the RE group (211.5±10.0) than in the group without 
RE (188.7±8.1). In contrast, triglyceride levels showed no sig-
Table 5. Multivariate Analysis of Reflux Esophagitis Development during the 2-Year Follow-Up
Variable  Non-reflux esophagitis (n=409) Reflux esophagitis (n=43) OR  95% CI
Age, yr  7.11 1.92-26.41
   16-39   46 (11.3)   5 (11.6)
   40-59 232 (56.7) 16 (37.2)
   ≥60 131 (32.0) 22 (51.2)
Alcohol consumption  (n=340) (n=30) 4.43 1.03-19.19
   Nonalcohol-nonalcohol 199 (58.5)   9 (30.0)
   Nonalcohol-alcohol   37 (10.9)   3 (10.0)
   Alcohol-nonalcohol   4 (1.2) 0 (0)
   Alcohol-alcohol 100 (29.4) 18 (60.0)
F/U cholesterol ≥200 mg/dL 188.7±8.1 211.5±10.0 5.03 1.32-19.17
Data are presented as mean±SD or number (%).
OR, odds ratio; CI, confidence interval; F/U, follow-up.Kim N, et al: Eradication of H. pylori and Reflux Esophagitis  443
nificant association with the development of RE.  
Among the significant findings identified by the univariate 
analysis, the following were identified as significant risk factors 
for RE development by multivaraiate analysis: age ≥60 years vs 
below 60 years (odds ratio [OR], 7.11; 95% confidence interval 
[CI], 1.92 to 26.41), alcohol consumption at follow-up (OR, 4.43; 
95% CI, 1.03 to 19.19), and elevated follow-up cholesterol levels 
(OR, 5.03; 95% CI, 1.32 to 19.17) (Table 5). 
DISCUSSION
Since H. pylori is a major cause of gastric cancer, eradication 
of H. pylori infections has become an important goal for the 
prevention of gastric cancer in high-risk groups. In South Korea, 
H. pylori eradication has rapidly increased from 13.9% in 2005
19 
to 37.4% in 2007 among subjects presenting for a health check-
up.
20 In addition, the prevalence of RE
21 or Barrett’s esophagus 
is increasing
22 similar to other Asian countries. Furthermore, 
since the rates of on demand H. pylori treatment or relapse in 
RE patients are also high in South Korea,
15 it is very important 
to determine whether the risk of GERD or RE increases after 
H. pylori eradication. There have been several reports suggest-
ing that GERD occurs after eradication of H. pylori in patients 
with or without peptic ulcers.
8,9,27-30 This development of GERD 
following the eradication of H. pylori might be related to an 
increase in refluxate acidity due to the disappearance of the   
neutralizing effect of bacterial ammonia production and corpus 
gastritis induced by persistent H. pylori infection.
31,32 In contrast, 
there have been some reports of the beneficial effect of H. pylori 
eradication for ameliorating symptoms of GERD.
12-16 The reason 
for these conflicting reports could originate from the underlying 
gastric mucosal status. For instance, a meta-analysis showed 
that the frequency of GERD is not increased after eradication 
of H. pylori among dyspeptic patients, but there was the risk of 
GERD development increased 2-fold after H. pylori eradication 
among patients with peptic ulcers.
33 Similarly, the univariate 
analysis of the present multicenter prospective study showed 
that the development of RE was more frequent after treating 
active or healing cases of BGU (16.5%) or DU (11.8%) than gas-
tritis (5.9%) (p=0.012) although this significance was not found 
in the multivariate analysis. In addition, PG I levels and PG I/
II ratios, which have been used as indicators of acid secretion,
34 
were found to be significantly higher in the group that devel-
oped RE compared to the nonRE group. This could support the 
hypothesis that acid secretion determines the development of 
RE.
A lack of association between RE or GERD symptoms and H. 
pylori eradication in the present study might reflect the lower 
prevalence of RE or GERD in South Korea compared to other 
Eastern as well as Western countries. The prevalence of RE has 
increased in Japan from 3% in the late 1970s to 10% to 15% 
in the late 1990s based on the results of upper-gastrointestinal 
endoscopies,
35 and from 2.7% in the early 1990s to 13.4% in 
2000 to 2001 in a Malaysian study.
36 In a South Korean study 
conducted in 1999, the prevalence of RE was 5.3% for patients 
with gastrointestinal symptoms,
37 and was 3.4% in a group 
of asymptomatic subjects presenting for a health check-up in 
2001.
38 In 2006 RE prevalence increased to 7.9% among sub-
jects presenting for a health check-up,
21 which is still lower than 
the levels reported in other Asian countries like Japan
35,39 and 
Malaysia.
36 Furthermore, the degree of RE found in the pres-
ent study was relatively mild. That is, 39 out of 43 RE subjects 
(90.7%) had LA-A, while only four were found to have LA-B 
(9.3%). In addition, among 30 patients who participated in the 
follow-up during the second year 27 patients did not show defi-
nite mucosal breaks around z-line, suggesting that RE could be 
transient, which is consistent with the findings of a Japanese 
study.
5 Still, the precise reasons why the prevalence of RE or 
GERD is lower in South Korea than other Asian countries is 
not clear. This might be related to life style factors such as the 
consumption of certain kinds of food or a high prevalence of 
atrophic gastritis
21 due to the high infection rate of H. pylori.
19 
Comparative studies on the prevalence of RE or GERD and its 
associated factors among South Korea and other Asian coun-
tries could help clarify this issue. 
Another explanation for a lack of association between RE 
and H. pylori eradication in the present study could be related 
to the absence of definite weight gain after H. pylori eradication 
in Koreans. Previous studies showed that H. pylori infection is 
inversely related to obesity
40,41 and that increased body weight 
is often observed after H. pylori eradication.
42 Since ghrelin 
is mainly synthesized and secreted by the gastric mucosa, the 
inverse effect of H. pylori infection on body weight has been 
attributed to the difference in plasma ghrelin concentrations 
in patients with or without H. pylori infections.
43 However, 
in the present study there was no definite weight change ob-
served according to H. pylori infection at the enrollment or H. 
pylori eradication after 2 years of follow-up. Since most of the 
previous studies were performed during short term follow-up 
(e.g., 12 weeks) after successful eradication,
40 it is possible that 
weight gain after H. pylori infection, which could be related to 
the increase of ghrelin, might be temporary. However, as the 
weight gain after successful H. pylori eradication was frequently 
observed in Japanese patients,
42 further study is necessary to 
confirm this finding in Koreans.
One of the characteristics of Korean patients with GERD is 
that they frequently complain of epigastric soreness or epigas-
tric pain, which is usually classified as symptom of functional 
dyspepsia. This was similar to a Korean report showing that 
18.8% patients that complained of functional dyspeptic symp-
toms were found to have RE and while 27.6% of patients with 
epigastric pain had RE.
44 This is the reason why epigastric sore-
ness was included as one of the reflux symptoms in our study. 
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on H. pylori eradication during the 2-year follow-up, there was 
no association of new development of any GERD symptoms 
(heartburn, acid regurgitation, chest pain, hoarseness, globus 
sensation, cough, or epigastric soreness) with H. pylori eradica-
tion. This fingding is rather different from the results of a Japa-
nese study.
14
In the present study, the incidence of RE per year regardless 
of H. pylori eradication was 7.3%, which is similar to the RE 
prevalence rate, 7.9% reported in 2006.
21 Since RE was transient 
in the present study, new development and the disappearance 
of RE might be somehow balanced among Koreans. In addition, 
the rate of newly developed GERD symptoms (heartburn, acid 
regurgitation, chest pain, hoarseness, globus sensation, cough, 
and epigastric soreness) during the 2-year follow-up was only 
0% to 10.45%. This is similar to the finding that the prevalence 
of GERD according to symptom occurrence was found to be 
5.1% among health check-up subjects in 2006,
21 and 3.5% in 
the rural and urban areas of Asan-si in South Korea, in a 2000 
to 2001 survey (n=1,471).
45 So far, there has been no prospec-
tive multicenter study examining the incidence of RE or GERD 
symptoms, nor the relationship of H. pylori eradication with RE 
or GERD symptoms in South Korea. From this point of view, the 
multicenter, prospective study presented here is very meaning-
ful as it has provided clues regarding the incidence of RE and 
GERD symptoms among South Koreans.
The significant risk factors for reflux esophagitis are known 
to include male gender, alcohol consumption, smoking, BMI 
≥25, abdominal obesity, and metabolic syndrome.
21,46,47 Similar-
ly, the multivaraiate analysis of the present study showed that 
an age ≥60 (OR, 7.11; 95% CI, 1.92 to 26.41), alcohol consump-
tion at follow-up (OR, 4.43; 95% CI, 1.03 to 19.2), and elevated 
cholesterol levels at follow-up (OR, 5.03; 95% CI, 1.32 to 19.2) 
were risk factors for the development of RE. Therefore, persons 
of advanced age (≥60 years-old) with significant alcohol intake 
and cholesterol levels over 200 mg/dL should be watchful for 
the development of RE. 
The present study had several limitations. First, there was a 
significant 1-year endoscopic follow-up loss after initial en-
rollmen. Most of this follow-up loss may have occurred when 
the patients did not have any reflux or dyspeptic symptoms. 
Biennial endoscopy or barium gastrography has actually been 
recommended for gastric cancer screening starting at the age of 
40 by the South Korean government since 2001. However, there 
was no statistical difference in gender, age, BMI, endoscopic 
diagnosis, smoking habits, alcohol use, occurrence of hiatal 
hernias, cholesterol levels, triglycerides, H. pylori infection, or 
pepsinogen levels between the 1,489 initially enrolled patients 
and 452 follow-up subjects. Second, the follow-up period was 
probably too short to detect the effect of H. pylori eradication 
on RE development. However, as pepsinogen I or PG I/II ratio 
reflecting the gastric acid secretion
34 has been already increased 
up to the level of H. pylori-negative group 1 year after H. py-
lori eradication in Koreans,
21 there might be little possibility of 
further occurrence of RE due to H. pylori eradication after long-
tem follow-up more than 2 years. 
In conclusion, our study demonstrated that the eradication of 
H. pylori did not cause the development of RE or GERD symp-
toms over 2 years of follow-up. These results support the hy-
pothesis that H. pylori eradication could be performed in South 
Korea without concerns about an increased risk of GERD or RE 
development. 
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